An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) mutations drive non-small cell lung cancer (NSCLC) and predict response to anilinoquinazoline inhibitors.
• Clinical resistance to EGFR inhibitors is a significant challenge in NSCLC treatment.
• A secondary T790M mutation in EGFR confers resistance to first-generation EGFR inhibitors.

Purpose of the Study:

• To establish a functional cell line model for studying EGFR signaling and T790M-mediated resistance.
• To evaluate the efficacy of CL-387,785 in overcoming T790M-induced resistance.
• To provide a platform for screening novel EGFR inhibitors.

Main Methods:

• Development of a stable Ba/F3 cell line system expressing wild-type, L858R, or T790M mutant EGFR.
• Treatment of engineered cells with gefitinib, erlotinib, and CL-387,785.
• Assessment of cell growth, apoptosis, and downstream signaling pathway inhibition.

Main Results:

• Gefitinib and erlotinib induced growth arrest and apoptosis in cells with wild-type or L858R EGFR but were ineffective against T790M mutant EGFR.
• The T790M mutation conferred high-level functional resistance to gefitinib and erlotinib.
• CL-387,785 demonstrated efficacy against T790M-mediated resistance by inhibiting downstream signaling pathways.
• Similar results were observed using the H1975 NSCLC cell line.

Conclusions:

• The established Ba/F3 cell line model effectively recapitulates EGFR T790M-mediated resistance.
• CL-387,785 overcomes functional resistance caused by the EGFR T790M mutation.
• This model system is valuable for screening new EGFR inhibitors targeting resistance mutations, supporting clinical investigation of compounds like CL-387,785 for resistant NSCLC.